Hyloris Pharmaceuticals SA
A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.
HYL | BR
Overview
Corporate Details
- ISIN(s):
- BE0974363955
- LEI:
- 875500LZIWS7QEQE0I73
- Country:
- Belgium
- Address:
- Boulevard de Patience et Beaujonc 3, 4000 Liège
- Website:
- https://hyloris.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Hyloris Pharmaceuticals SA is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address unmet medical needs. The company's core strategy involves reformulating and repurposing established drugs by leveraging abbreviated regulatory pathways, such as the U.S. FDA's 505(b)(2) framework. This approach aims to reduce development timelines, costs, and risks. Hyloris has built a broad, patented portfolio of value-added medicines designed to offer significant improvements for patients, healthcare professionals, and payors. Its commercialized products include Sotalol IV for atrial fibrillation and Maxigesic® IV, a non-opioid post-operative pain treatment. The company also develops and markets high-barrier generic products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-25 00:07 |
Earnings Release
PR Half Year Results 2025_EN final.pdf
|
English | 392.0 KB | ||
| 2025-09-25 00:07 |
Earnings Release
PR Half Year Results 2025_FR final.pdf
|
French | 317.6 KB | ||
| 2025-09-25 00:07 |
Earnings Release
PR Half Year Results 2025_EN final.pdf
|
English | 392.0 KB | ||
| 2025-09-25 00:07 |
Earnings Release
PR Half Year Results 2025_FR final.pdf
|
French | 317.6 KB | ||
| 2025-09-25 00:07 |
Interim Report
2025 06 30 Hyloris HY report_EN final.pdf
|
English | 1.3 MB | ||
| 2025-09-25 00:07 |
Interim Report
2025 06 30 Hyloris HY report_FR final.pdf
|
French | 978.2 KB | ||
| 2025-08-22 07:00 |
M&A Activity
Press Release Hyloris Signs XTRAZA Licensing Agreement with HUONS.pdf
|
English | 206.8 KB | ||
| 2025-08-22 07:00 |
M&A Activity
PR Hyloris Signs XTRAZA Licensing Agreement with Huons FR.pdf
|
French | 221.6 KB | ||
| 2025-07-17 07:00 |
Regulatory News Service
Press Release_ Atomoxetine Clinical Trial_EN.pdf
|
English | 221.8 KB | ||
| 2025-07-17 07:00 |
Regulatory News Service
Press Release_Atomoxetine Clinical Trial_FR.pdf
|
French | 248.2 KB | ||
| 2025-07-17 07:00 |
Regulatory News Service
Press Release_ Atomoxetine Clinical Trial_EN.pdf
|
English | 221.8 KB | ||
| 2025-07-17 07:00 |
Regulatory News Service
Press Release_Atomoxetine Clinical Trial_FR.pdf
|
French | 248.2 KB | ||
| 2025-06-23 07:00 |
M&A Activity
PR Hyloris_Kuvatris Therapeutics_Partnership EN.pdf
|
English | 251.4 KB | ||
| 2025-06-23 07:00 |
Share Issue/Capital Change
PR Hyloris_Kuvatris Therapeutics_Partenariat FR.pdf
|
French | 289.9 KB | ||
| 2025-06-10 20:00 |
Post-Annual General Meeting Information
PR AGM 2025 - Hyloris EN.pdf
|
English | 140.7 KB |
Automate Your Workflow. Get a real-time feed of all Hyloris Pharmaceuticals SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Hyloris Pharmaceuticals SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Hyloris Pharmaceuticals SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-13 | Aichhorn Dietmar | Executive member | Buy | 12,500 | 144,375.00 EUR |
| 2023-06-13 | Vandebroek Jean-Luc | Executive member | Buy | 6,000 | 69,300.00 EUR |
| 2022-04-14 | Van der Elst Koenraad | Executive member | Sell | 3,312 | 56,466.40 EUR |
| 2022-03-22 | Aichhorn Dietmar | Executive member | Buy | 20,000 | 347,000.00 EUR |
| 2022-03-22 | Vandebroek Jean-Luc | Board | Buy | 3,000 | 52,050.00 EUR |
